Crispr Therapeutics AG's total assets for Q2 2025 were $2.03B, a decrease of -6.30% from the previous quarter. CRSP total liabilities were $318.59M for the fiscal quarter, a -5.45% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.